Alvotech
ALVOPhase 3Alvotech is a purpose-driven biosimilar company with a mission to improve lives by expanding global access to affordable biologic medicines. The company leverages a fully integrated platform from cell line development to commercial manufacturing to achieve speed and control. Its strategic pipeline includes several approved biosimilars, such as AVT02 (adalimumab), and a deep portfolio targeting major immunology and oncology drugs. Alvotech is publicly traded and partners with commercialization experts to bring its products to market worldwide.
ALVO · Stock Price
Historical price data
AI Company Overview
Alvotech is a purpose-driven biosimilar company with a mission to improve lives by expanding global access to affordable biologic medicines. The company leverages a fully integrated platform from cell line development to commercial manufacturing to achieve speed and control. Its strategic pipeline includes several approved biosimilars, such as AVT02 (adalimumab), and a deep portfolio targeting major immunology and oncology drugs. Alvotech is publicly traded and partners with commercialization experts to bring its products to market worldwide.
Technology Platform
A fully integrated, vertically controlled biosimilar development and manufacturing platform encompassing proprietary cell line development, process development, analytical characterization, and commercial-scale fill/finish production.
Pipeline Snapshot
1717 drugs in pipeline, 8 in Phase 3
| Drug | Indication | Stage |
|---|---|---|
| AVT16 + Vedolizumab | Ulcerative Colitis | Phase 3 |
| AVT29 (proposed aflibercept HD biosimilar) + Eylea HD (aflibercept HD) | Diabetic Macular Edema | Phase 3 |
| AVT03 + Denosumab | Osteoporosis, Postmenopausal | Phase 3 |
| Adalimumab originator + Adalimumab biosimilar | Plaque Psoriasis | Phase 3 |
| AVT06 (proposed aflibercept biosimilar) + Eylea® (Aflibercept) | Neovascular (Wet) AMD | Phase 3 |
Funding History
4Total raised: $1.2B
Opportunities
Risk Factors
Competitive Landscape
Alvotech competes with large pharma biosimilar players (Amgen, Pfizer, Sandoz) and specialized biosimilar firms (Celltrion, Samsung Bioepis). Its differentiation lies in its fully integrated platform, focus on high-concentration formulations, and strategic partnerships for commercialization.
Company Info
Trading
Contact
Therapeutic Areas
Sectors
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile